03/29/23 7:30 AMNasdaq : ABEO earningsAbeona Therapeutics Reports Full Year 2022 Financial Results and Provides Corporate UpdateExpects to submit BLA for EB-101 to FDA in late-2Q/early-3Q 2023 based on positive Phase 3 VIITAL™ study results announced in 4Q 2022 Advancing AAV-based gene therapy candidates toward IND studies in Stargardt Disease, X-linked Retinoschisis, and Autosomal Dominant Optic Atrophy Strengthened seniorRHEA-AIneutral
03/24/23 7:30 AMNasdaq : ABEO management Abeona Therapeutics Announces New Employee Inducement GrantsAbeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new employees who joined Abeona. On March 23, 2023, Abeona granted restricted stock equity awards to six employees as an inducement for them to acceptRHEA-AIvery positive
03/16/23 7:30 AMNasdaq : ABEO clinical trialAbeona Therapeutics Announces Acceptance of Abstract on EB-101 Phase 3 VIITAL™ Study Results for Oral Presentation at International Societies for Investigative Dermatology (ISID) 2023 MeetingAbeona Therapeutics Inc. (Nasdaq: ABEO) today announced that additional data from its pivotal Phase 3 VIITAL™ study of EB-101 for recessive dystrophic epidermolysis bullosa (RDEB) has been accepted for an oral presentation at theRHEA-AIneutral
03/14/23 7:30 AMNasdaq : ABEO Abeona Therapeutics Announces Update on AAV Ophthalmology ProgramAdvancing AAV-based gene therapy candidates toward IND studies on encouraging animal proof of concept data in Stargardt Disease, X-linked Retinoschisis (XLRS), and Autosomal Dominant Optic Atrophy (ADOA) To submit first pre-Investigational New Drug (IND) application meeting request this month NEWRHEA-AIpositive
11/14/22 7:30 AMNasdaq : ABEO earningsAbeona Therapeutics Reports Third Quarter 2022 Financial ResultsAbeona Therapeutics Inc.RHEA-AIneutral
11/03/22 7:31 AMNasdaq : ABEO Abeona Therapeutics Announces $35 Million Private Placement FinancingAbeona Therapeutics Inc. (Nasdaq: ABEO) announced today that it has entered into a securities purchase agreement to sell 7,065,946 shares of its common stock, and, in lieu of shares of common stock, pre-funded warrants exercisable forRHEA-AIneutral
11/03/22 7:30 AMNasdaq : ABEO clinical trialAbeona Therapeutics Announces Positive Topline Results with Both Co-Primary Endpoints Met in Pivotal Phase 3 VIITAL™ Study of EB-101Co-primary endpoint measuring 50% wound healing, other endpoints measuring 75% and complete wound healing at six months all met Co-primary endpoint measuring pain reduction at six months met; greater magnitude of pain reduction benefit was observed in post-hoc analysis of EB-101 treated wounds withRHEA-AIpositive
10/19/22 7:30 AMNasdaq : ABEO clinical trialAbeona Therapeutics Announces Database Lock for Pivotal Phase 3 VIITAL™ Study of EB-101 in Patients with Recessive Dystrophic Epidermolysis Bullosa (RDEB) Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced the database lock on October 18, 2022 for the pivotal Phase 3 VIITAL™ study of its investigational autologous, engineered cell therapy, EB-101, in patients with recessive dystrophicRHEA-AIneutral
10/04/22 7:30 AMNasdaq : ABEO clinical trialAbeona Therapeutics Announces Completion of Patient Follow-up in Pivotal Phase 3 VIITAL™ Study of EB-101 in Patients with Recessive Dystrophic Epidermolysis Bullosa (RDEB)Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that the last patient has completed their 6-month follow-up visit in Abeona’s pivotal Phase 3 VIITAL™ study of itsRHEA-AIneutral
09/22/22 7:30 AMNasdaq : ABEO conferencesAbeona Therapeutics to Participate in the Jefferies Cell and Genetic Medicine SummitAbeona Therapeutics Inc. (Nasdaq: ABEO) today announced that Vish Seshadri, Chief Executive Officer of Abeona, will participate in a fireside chat at the Jefferies Cell and Genetic Medicine Summit on Friday, September 30, 2022 at 8:30RHEA-AIneutral